Managing Hyperkalemia in Patients with Impaired Renal Function

Introduction to Hyperkalemia Management

The American Heart Association recommends stopping losartan temporarily until potassium normalizes to 4.0-5.0 mEq/L in patients with hyperkalemia (K+ 5.6 mEq/L) and impaired renal function (GFR 56 mL/min) 1, 2
The American College of Cardiology suggests rechecking potassium and creatinine within 3-7 days after stopping losartan in patients with hyperkalemia and impaired renal function (GFR 56 mL/min) 1, 3

The National Kidney Foundation recommends implementing dietary potassium restriction and considering a potassium binder (patiromer or sodium zirconium cyclosilicate) if an angiotensin receptor blocker (ARB) needs to be maintained for cardiac/renal protection in patients with hyperkalemia (K+ >5.0 mEq/L) and impaired renal function (GFR 56 mL/min) 2
The American Heart Association advises against continuing losartan at the current dose with K+ 5.6 mEq/L, as this risks life-threatening arrhythmias, and recommends restarting losartan at a reduced dose (25 mg daily) with concurrent potassium binder if needed for cardiac/renal protection once potassium normalizes 1, 2

The American College of Cardiology suggests switching to a calcium channel blocker (amlodipine 2.5-10 mg daily) which doesn't affect potassium, or adding/increasing metoprolol for blood pressure control without potassium effects in patients with hyperkalemia and impaired renal function (GFR 56 mL/min) 3

The National Kidney Foundation recommends rechecking potassium, sodium, creatinine, and GFR within 3-7 days after stopping losartan, and targeting a potassium range of 4.0-5.0 mEq/L to minimize cardiac risk in patients with hyperkalemia and impaired renal function (GFR 56 mL/min) 1, 2
The American Heart Association advises monitoring potassium and renal function monthly for 3 months, then every 3-6 months, in patients with hyperkalemia and impaired renal function (GFR 56 mL/min) 1, 3